vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FIRST HAWAIIAN, INC. (FHB). Click either name above to swap in a different company.

FIRST HAWAIIAN, INC. is the larger business by last-quarter revenue ($220.3M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 3.8%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

First Hawaiian, Inc. is a bank holding company headquartered in Honolulu, Hawaiʻi. Its principal subsidiary, First Hawaiian Bank, founded in 1858, is Hawaiʻi’s oldest and largest financial institution headquartered in Honolulu at the First Hawaiian Center. The bank has 57 branches throughout Hawaiʻi, three in Guam and one in Saipan. It offers banking services to consumer and commercial customers, including deposit products, lending services and wealth management, insurance, private banking an...

ESPR vs FHB — Head-to-Head

Bigger by revenue
FHB
FHB
1.3× larger
FHB
$220.3M
$168.4M
ESPR
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
3.8%
FHB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
FHB
FHB
Revenue
$168.4M
$220.3M
Net Profit
$67.8M
Gross Margin
Operating Margin
50.6%
Net Margin
30.8%
Revenue YoY
143.7%
Net Profit YoY
14.4%
EPS (diluted)
$0.32
$0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
FHB
FHB
Q1 26
$220.3M
Q4 25
$168.4M
$225.9M
Q3 25
$87.3M
$226.4M
Q2 25
$82.4M
$217.5M
Q1 25
$65.0M
$211.0M
Q4 24
$69.1M
$188.1M
Q3 24
$51.6M
$210.0M
Q2 24
$73.8M
$204.6M
Net Profit
ESPR
ESPR
FHB
FHB
Q1 26
$67.8M
Q4 25
$69.9M
Q3 25
$-31.3M
$73.8M
Q2 25
$-12.7M
$73.2M
Q1 25
$-40.5M
$59.2M
Q4 24
$52.5M
Q3 24
$-29.5M
$61.5M
Q2 24
$-61.9M
$61.9M
Operating Margin
ESPR
ESPR
FHB
FHB
Q1 26
Q4 25
50.6%
41.2%
Q3 25
-11.4%
42.5%
Q2 25
8.6%
40.5%
Q1 25
-34.0%
36.5%
Q4 24
-6.4%
34.4%
Q3 24
-31.0%
36.4%
Q2 24
3.5%
39.5%
Net Margin
ESPR
ESPR
FHB
FHB
Q1 26
30.8%
Q4 25
31.0%
Q3 25
-35.9%
32.6%
Q2 25
-15.4%
33.7%
Q1 25
-62.2%
28.1%
Q4 24
27.9%
Q3 24
-57.2%
29.3%
Q2 24
-83.9%
30.3%
EPS (diluted)
ESPR
ESPR
FHB
FHB
Q1 26
$0.55
Q4 25
$0.32
$0.56
Q3 25
$-0.16
$0.59
Q2 25
$-0.06
$0.58
Q1 25
$-0.21
$0.47
Q4 24
$-0.14
$0.41
Q3 24
$-0.15
$0.48
Q2 24
$-0.33
$0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
FHB
FHB
Cash + ST InvestmentsLiquidity on hand
$167.9M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$-302.0M
$2.8B
Total Assets
$465.9M
$24.3B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
FHB
FHB
Q1 26
Q4 25
$167.9M
Q3 25
$92.4M
Q2 25
$86.1M
Q1 25
$114.6M
Q4 24
$144.8M
Q3 24
$144.7M
Q2 24
$189.3M
Total Debt
ESPR
ESPR
FHB
FHB
Q1 26
$0
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
ESPR
ESPR
FHB
FHB
Q1 26
$2.8B
Q4 25
$-302.0M
$2.8B
Q3 25
$-451.4M
$2.7B
Q2 25
$-433.5M
$2.7B
Q1 25
$-426.2M
$2.6B
Q4 24
$-388.7M
$2.6B
Q3 24
$-370.2M
$2.6B
Q2 24
$-344.2M
$2.6B
Total Assets
ESPR
ESPR
FHB
FHB
Q1 26
$24.3B
Q4 25
$465.9M
$24.0B
Q3 25
$364.0M
$24.1B
Q2 25
$347.1M
$23.8B
Q1 25
$324.0M
$23.7B
Q4 24
$343.8M
$23.8B
Q3 24
$314.1M
$23.8B
Q2 24
$352.3M
$24.0B
Debt / Equity
ESPR
ESPR
FHB
FHB
Q1 26
0.00×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
FHB
FHB
Operating Cash FlowLast quarter
$45.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
FHB
FHB
Q1 26
Q4 25
$45.2M
$335.1M
Q3 25
$-4.3M
$57.1M
Q2 25
$-31.4M
$136.4M
Q1 25
$-22.6M
$36.7M
Q4 24
$-35.0M
$317.5M
Q3 24
$-35.3M
$58.9M
Q2 24
$-7.2M
$78.2M
Free Cash Flow
ESPR
ESPR
FHB
FHB
Q1 26
Q4 25
$303.3M
Q3 25
$49.5M
Q2 25
$125.2M
Q1 25
$28.6M
Q4 24
$288.7M
Q3 24
$-35.5M
$52.3M
Q2 24
$-7.3M
$72.2M
FCF Margin
ESPR
ESPR
FHB
FHB
Q1 26
Q4 25
134.3%
Q3 25
21.9%
Q2 25
57.5%
Q1 25
13.6%
Q4 24
153.5%
Q3 24
-68.7%
24.9%
Q2 24
-9.9%
35.3%
Capex Intensity
ESPR
ESPR
FHB
FHB
Q1 26
Q4 25
0.0%
14.1%
Q3 25
0.0%
3.3%
Q2 25
0.0%
5.2%
Q1 25
0.0%
3.8%
Q4 24
0.0%
15.3%
Q3 24
0.3%
3.1%
Q2 24
0.1%
2.9%
Cash Conversion
ESPR
ESPR
FHB
FHB
Q1 26
Q4 25
4.79×
Q3 25
0.77×
Q2 25
1.86×
Q1 25
0.62×
Q4 24
6.05×
Q3 24
0.96×
Q2 24
1.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

FHB
FHB

Net Interest Income$167.5M76%
Noninterest Income$52.8M24%

Related Comparisons